argenx Unveils Positive Phase 2 Results for Efgartigimod in Myositis and Sjogren’s Disease at EULAR 2025 argenx SE a global immunology company dedicated to advancing treatments for severe autoimmune diseases,…
Bayer and Broad Institute Extend Landmark Collaboration to Advance Cardiovascular Genomics and Precision Medicine In a bold continuation of a decade-long scientific alliance, Bayer and the Broad Institute of MIT…
Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive…
Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the…
FDA Expands Approval of AbbVie’s MAVYRET® as First and Only 8-Week Treatment for Acute Hepatitis C in Adults and Children Aged 3 and Above AbbVie has received a significant regulatory…
Ascendis Pharma Reports Promising Week 26 Results from COACH Trial: TransCon hGH Enhances TransCon CNP Benefits in Children with Achondroplasia Ascendis Pharma A/S, a global biopharmaceutical company focused on developing…
WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health…
Jazz Pharmaceuticals Showcases Promising Phase 4 Results for Xywav® in Narcolepsy at SLEEP 2025, Underscoring Cardiovascular and Symptom Management Benefits Jazz Pharmaceuticals plc presented compelling new late-breaking data at the…
WuXi Biologics and VISEN Pharmaceuticals Expand Partnership to Localize Production of Lonapegsomatropin in China WuXi Biologics ,a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, and VISEN…
Alnylam Secures European Commission Approval for AMVUTTRA® to Treat Cardiomyopathy in ATTR Amyloidosis Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) therapeutics, has received European Commission (EC) approval for…
Merck’s Pimicotinib Accepted for Priority Review in China, Offering Hope for Patients with TGCT Merck, a prominent global science and technology company, announced a significant milestone in its oncology portfolio…
Sanofi Ramps Up Early Global Distribution of Beyfortus to Meet Growing RSV Season Demand, Enhancing Protection for Infants Worldwide In a proactive move to ensure readiness for the 2025-2026 respiratory…